Argenta Discovery has announced that it has entered into drug discovery collaboration with Cellzome, Inc.
Under the terms of the agreement Argenta will apply its integrated medicinal chemistry, assay development and screening capabilities and collaborate with Cellzome’s scientists in the search for disease therapies.
The deal also provides Cellzome with access to Argenta's other integrated scientific disciplines including ADME/PK.
Dr Chris Ashton, Argenta's CEO, said, “We are delighted that one of Europe's leading biotechnology companies has chosen to work with Argenta.”
He adds, “This new agreement illustrates Argenta’s excellence in providing fully integrated collaborative drug discovery solutions.”
Further he said, “Last year our contract research business revenue grew by over 25% and we have had an excellent start to the new financial year: this being the third collaborative agreement we have signed in the last five months.”
Tim Edwards, CEO of Cellzome, added, “We chose to work with Argenta because of the experience of the Argenta team; they can provide us with high quality, reproducible results.”
He adds, "This collaboration will further extend and compliment our own drug discovery unit and will help us move our projects forwards into the clinic."